Ocular Therapeutix (NASDAQ:OCUL) Shares Down 5.5%

Share on StockTwits

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) were down 5.5% during trading on Friday . The stock traded as low as $4.41 and last traded at $4.43, approximately 522,601 shares traded hands during trading. A decline of 23% from the average daily volume of 675,979 shares. The stock had previously closed at $4.69.

Several equities analysts have commented on OCUL shares. ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Piper Jaffray Companies set a $8.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a research report on Friday, July 26th. HC Wainwright set a $9.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a research report on Tuesday, July 2nd. JMP Securities set a $9.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a research report on Friday, June 21st. Finally, Raymond James lowered shares of Ocular Therapeutix from a “strong-buy” rating to an “outperform” rating and lowered their price objective for the company from $11.00 to $5.00 in a research report on Tuesday, May 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Ocular Therapeutix currently has an average rating of “Hold” and a consensus price target of $9.18.

The company’s fifty day moving average price is $4.73 and its 200-day moving average price is $4.07. The stock has a market cap of $221.35 million, a P/E ratio of -2.82 and a beta of 2.25. The company has a debt-to-equity ratio of 7.06, a quick ratio of 6.39 and a current ratio of 6.46.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.15). The firm had revenue of $0.65 million during the quarter, compared to the consensus estimate of $1.00 million. Ocular Therapeutix had a negative return on equity of 256.69% and a negative net margin of 3,450.84%. Analysts anticipate that Ocular Therapeutix Inc will post -1.59 earnings per share for the current fiscal year.

In related news, CEO Antony C. Mattessich purchased 40,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, June 6th. The shares were bought at an average price of $2.81 per share, with a total value of $112,400.00. Following the purchase, the chief executive officer now directly owns 97,900 shares of the company’s stock, valued at approximately $275,099. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Amarpreet Sawhney purchased 45,780 shares of Ocular Therapeutix stock in a transaction that occurred on Wednesday, June 5th. The stock was bought at an average cost of $2.91 per share, for a total transaction of $133,219.80. Following the purchase, the chairman now directly owns 898,711 shares in the company, valued at $2,615,249.01. The disclosure for this purchase can be found here. Insiders bought a total of 229,248 shares of company stock valued at $669,811 in the last 90 days. Company insiders own 16.10% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its position in shares of Ocular Therapeutix by 36.2% in the second quarter. Royal Bank of Canada now owns 147,478 shares of the biopharmaceutical company’s stock valued at $648,000 after buying an additional 39,218 shares in the last quarter. Man Group plc increased its position in shares of Ocular Therapeutix by 25.2% in the second quarter. Man Group plc now owns 2,158,149 shares of the biopharmaceutical company’s stock valued at $9,496,000 after buying an additional 434,693 shares in the last quarter. Sio Capital Management LLC purchased a new position in shares of Ocular Therapeutix in the second quarter valued at $263,000. Vanguard Group Inc. increased its position in shares of Ocular Therapeutix by 14.3% in the second quarter. Vanguard Group Inc. now owns 1,871,947 shares of the biopharmaceutical company’s stock valued at $8,236,000 after buying an additional 234,360 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Ocular Therapeutix by 3.4% in the second quarter. BlackRock Inc. now owns 2,940,745 shares of the biopharmaceutical company’s stock valued at $12,939,000 after buying an additional 97,433 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile (NASDAQ:OCUL)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Featured Story: Green Investing

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Icahn Enterprises LP  Stock Holdings Lessened by Round Hill Asset Management
Icahn Enterprises LP Stock Holdings Lessened by Round Hill Asset Management
S&T Bank PA Increases Position in Hercules Capital Inc
S&T Bank PA Increases Position in Hercules Capital Inc
S&T Bank PA Cuts Stock Holdings in FMC Corp
S&T Bank PA Cuts Stock Holdings in FMC Corp
S&T Bank PA Has $9.03 Million Stock Position in Cummins Inc.
S&T Bank PA Has $9.03 Million Stock Position in Cummins Inc.
Round Hill Asset Management Sells 2,234 Shares of Hometrust Bancshares Inc
Round Hill Asset Management Sells 2,234 Shares of Hometrust Bancshares Inc
Bodhi [ETH] Price Up 80.3% This Week
Bodhi [ETH] Price Up 80.3% This Week


 
© 2006-2019 Zolmax.